Clinical Trials
14 trialsNCT03292133 2025-06-10
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT03599518 2023-02-08
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Terminated
NCT02025218 2021-04-01
IRENE
Amsterdam UMC, location VUmc
Phase 2 Terminated
NCT02893332 2021-02-03
Sindas
Sichuan Provincial People's Hospital
Phase 3 Terminated
NCT02326285 2018-01-23
NeoIntercal
AIO-Studien-gGmbH
Phase 2/3 Terminated
NCT02299765 2017-11-27
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Sichuan University
Phase 4 Terminated
NCT01405846 2016-08-19
TIDAL1
Papworth Hospital NHS Foundation Trust
Phase 2 Terminated
NCT01363557 2014-05-13
ARPEGE
Assistance Publique - Hôpitaux de Paris
Phase NA Terminated
NCT00536107 2013-10-01
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 4 Terminated
NCT00104728 2012-10-31
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00091156 2012-07-16
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00234468 2011-05-20
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
AstraZeneca
Phase 3 Terminated
NCT00234442 2009-06-30
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
AstraZeneca
Phase 2 Terminated